Upgrade to SI Premium - Free Trial

Revolution Medicines (RVMD)

183.03 -0.26 (0.14%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

FDA accepts Revolution Medicines NDA for daraxonrasib in pancreatic cancer July 22, 2026 4:05 PM - StreetInsider Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer July 22, 2026 4:05 PM - Globe NewsWire Truist Securities Reiterates Buy Rating on Revolution (RVMD) July 10, 2026 9:10 AM - StreetInsider Revolution (RVMD) PT Raised to $235 at Guggenheim July 9, 2026 7:09 AM - StreetInsider EMA begins phased review of Revolution Medicines' daraxonrasib July 7, 2026 9:24 AM - StreetInsider European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process July 7, 2026 9:24 AM - Globe NewsWire Revolution (RVMD) PT Raised to $220 at UBS July 6, 2026 9:23 AM - StreetInsider Revolution (RVMD) PT Raised to $215 at Mizuho July 6, 2026 8:00 AM - StreetInsider Revolution (RVMD) PT Raised to $181 at Wedbush July 2, 2026 12:09 PM - StreetInsider Revolution Medicines reports Phase 1/2 data for zoldonrasib in pancreatic cancer July 2, 2026 8:01 AM - StreetInsider Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026  July 2, 2026 8:00 AM - Globe NewsWire Form 4 Revolution Medicines, For: Jun 29 Filed by: Patel Sushil July 1, 2026 6:25 PM - SEC Filing Revolution (RVMD) PT Raised to $210 at Truist Securities June 30, 2026 6:54 AM - StreetInsider Form 144 Revolution Medicines, Filed by: Patel Sushil June 29, 2026 4:45 PM - SEC Filing Revolution (RVMD) PT Raised to $235 at Needham June 29, 2026 8:18 AM - StreetInsider Form 4 Revolution Medicines, For: Jun 24 Filed by: Anders Jack June 26, 2026 4:10 PM - SEC Filing Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 June 24, 2026 7:31 PM - Globe NewsWire Form 144 Revolution Medicines, Filed by: Anders Jack June 24, 2026 4:36 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Kim Lorence H. June 23, 2026 5:57 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Borisy Alexis June 23, 2026 5:52 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: ANDERSON ELIZABETH M June 23, 2026 5:46 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Horning Sandra June 23, 2026 5:45 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Clyburn Frank June 23, 2026 5:44 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Patel Sushil June 23, 2026 5:44 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Borellini Flavia June 23, 2026 5:42 PM - SEC Filing Revolution Medicines starts Phase 3 trial of zoldonrasib for pancreatic cancer June 23, 2026 8:00 AM - StreetInsider Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met June 23, 2026 8:00 AM - Globe NewsWire RBC Capital Reiterates Outperform Rating on Revolution (RVMD) June 22, 2026 9:41 AM - StreetInsider Revolution Medicines R&D chief to step down ahead of 2027 retirement June 22, 2026 8:01 AM - StreetInsider Form 8-K Revolution Medicines, For: Jun 18 June 22, 2026 8:00 AM - SEC Filing Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. June 22, 2026 8:00 AM - Globe NewsWire Form 4 Revolution Medicines, For: Jun 16 Filed by: Mancini Anthony June 18, 2026 4:11 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: GOLDSMITH MARK A June 18, 2026 4:11 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: Cislini Jeff June 18, 2026 4:11 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: Anders Jack June 18, 2026 4:10 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: Kelsey Stephen Michael June 18, 2026 4:10 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 15 Filed by: Horn Margaret A June 17, 2026 7:52 PM - SEC Filing Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A June 15, 2026 6:30 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Cislini Jeff June 15, 2026 6:23 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Anders Jack June 15, 2026 6:16 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Mancini Anthony June 15, 2026 6:07 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Kelsey Stephen Michael June 15, 2026 6:00 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Horn Margaret A June 15, 2026 5:52 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Horn Margaret A June 15, 2026 5:00 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 11 Filed by: Horn Margaret A June 15, 2026 4:06 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Horn Margaret A June 11, 2026 4:28 PM - SEC Filing UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data Release June 9, 2026 9:24 AM - StreetInsider Revolution (RVMD) trading up 1%, RBC says that's about what they expected it to trade June 8, 2026 9:38 AM - StreetInsider Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion June 3, 2026 8:30 AM - StreetInsider Revolution (RVMD) PT Raised to $182 at RBC Capital June 2, 2026 5:03 AM - StreetInsider Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO June 2, 2026 4:19 AM - StreetInsider Revolution (RVMD) PT Raised to $195 at H.C. Wainwright June 1, 2026 10:45 AM - StreetInsider TD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD) June 1, 2026 8:28 AM - StreetInsider Revolution (RVMD) Reiterated at Buy by Stifel June 1, 2026 7:36 AM - StreetInsider Revolution (RVMD) PT Raised to $195 at Oppenheimer June 1, 2026 7:33 AM - StreetInsider Revolution Medicines reports positive pancreatic cancer trial results May 31, 2026 8:06 AM - StreetInsider Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic May 31, 2026 8:06 AM - Globe NewsWire Form 4 Revolution Medicines, For: May 26 Filed by: Mancini Anthony May 28, 2026 4:55 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Mancini Anthony May 26, 2026 4:47 PM - SEC Filing Bernstein SocGen Group Starts Revolution (RVMD) at Market Perform May 21, 2026 4:24 PM - StreetInsider Revolution Medicines schedules call on pancreatic cancer trial results May 21, 2026 4:13 PM - StreetInsider Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation May 21, 2026 4:05 PM - Globe NewsWire Truist Securities Assumes Revolution (RVMD) at Buy May 18, 2026 6:21 AM - StreetInsider Form SCHEDULE 13G/A Revolution Medicines, Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 11:24 AM - SEC Filing Revolution (RVMD) PT Raised to $165 at RBC Capital May 7, 2026 8:30 AM - StreetInsider Revolution (RVMD) PT Raised to $172 at Piper Sandler May 7, 2026 8:06 AM - StreetInsider Revolution (RVMD) PT Lowered to $183 at Needham May 7, 2026 7:24 AM - StreetInsider Revolution (RVMD) PT Raised to $205 at Guggenheim May 7, 2026 6:39 AM - StreetInsider Revolution Medicines publishes pancreatic cancer trial data in NEJM May 6, 2026 6:00 PM - StreetInsider Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer May 6, 2026 6:00 PM - Globe NewsWire Form 10-Q Revolution Medicines, For: Mar 31 May 6, 2026 4:12 PM - SEC Filing Form 8-K Revolution Medicines, For: May 06 May 6, 2026 4:05 PM - SEC Filing Revolution Medicines, Inc. (RVMD) Misses Q1 EPS by 46c, provides guidance May 6, 2026 4:05 PM - StreetInsider Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress May 6, 2026 4:02 PM - Globe NewsWire Revolution Medicines receives FDA early access authorization for pancreatic cancer pill May 1, 2026 12:54 PM - StreetInsider Form 4 Revolution Medicines, For: Apr 27 Filed by: Mancini Anthony April 29, 2026 5:51 PM - SEC Filing Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026 April 29, 2026 4:05 PM - Globe NewsWire TD Cowen Reiterates Buy Rating on Revolution (RVMD) April 28, 2026 10:57 AM - StreetInsider Form DEFA14A Revolution Medicines, April 28, 2026 6:05 AM - SEC Filing Form ARS Revolution Medicines, For: Dec 31 April 28, 2026 6:01 AM - SEC Filing Form DEF 14A Revolution Medicines, For: Jun 18 April 27, 2026 5:31 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Mancini Anthony April 27, 2026 4:33 PM - SEC Filing Revolution (RVMD) PT Raised to $185 at Mizuho April 23, 2026 4:35 AM - StreetInsider Full Article List